Sorrento Therapeutics (OTCPK:SRNE.Q) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

SRNE.Q 주식 개요

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain.

회사 소개

SRNE.Q 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	0/6
배당금	0/6

보상

위험 분석

지난 5년간 매년 수익이 27.1% 씩 감소했습니다.

최근 3개월간 주가 변동폭 심해

마이너스 주주 지분

cash runway 경력이 1년 미만입니다.

+ 2 더 많은 위험

Sorrento Therapeutics, Inc. 경쟁사

Celularity

NasdaqCM:CELU

US$65.7m

Exagen

NasdaqGM:XGN

US$54.6m

LAVA Therapeutics

NasdaqGS:LVTX

US$44.1m

Atara Biotherapeutics

NasdaqGS:ATRA

US$45.8m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Sorrento Therapeutics
과거 주가
현재 주가	US$0.11
52주 최고치	US$1.23
52주 최저치	US$0.021
베타	2.1
11개월 변경	159.95%
3개월 변경 사항	13.27%
1년 변경 사항	-90.59%
33년 변화	-98.50%
5년 변화	-95.49%
IPO 이후 변화	-99.11%

최근 뉴스 및 업데이트

Recent updates

Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M

Sep 29

Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial

Sep 15

Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103

Aug 31

Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC

Aug 23

Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading

Aug 17

주주 수익률

	SRNE.Q	US Biotechs	US 마켓
7D	-5.5%	-0.1%	0.8%
1Y	-90.6%	21.7%	33.4%

수익률 대 산업: SRNE.Q 지난 1년 동안 13.4 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: SRNE.Q 지난 1년 동안 24.7 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is SRNE.Q's price volatile compared to industry and market?
SRNE.Q volatility
SRNE.Q Average Weekly Movement	106.1%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.1%

안정적인 주가: SRNE.Q 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: SRNE.Q 의 주간 변동성은 지난 1년 동안 57% 에서 106% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
2006	949	Henry Ji	www.sorrentotherapeutics.com

Sorrento Therapeutics, Inc. 기본 사항 요약

Sorrento Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
SRNE.Q 기본 통계
시가총액	US$60.35m
수익(TTM)	-US$548.00m
수익(TTM)	US$64.27m

0.9x

P/S 비율

-0.1x

P/E 비율

SRNE.Q 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
SRNE.Q 손익 계산서(TTM)
수익	US$64.27m
수익 비용	US$221.74m
총 이익	-US$157.47m
기타 비용	US$390.53m
수익	-US$548.00m

최근 보고된 수익

Jun 30, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.01
총 마진	-245.01%
순이익 마진	-852.65%
부채/자본 비율	-71.8%

SRNE.Q 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

SRNE.Q 주식 개요

보상

위험 분석

Sorrento Therapeutics, Inc. 경쟁사

NasdaqCM:CELU

US$65.7m

NasdaqGM:XGN

US$54.6m

NasdaqGS:LVTX

US$44.1m

NasdaqGS:ATRA

US$45.8m

가격 내역 및 성능

최근 뉴스 및 업데이트

Final DIP Financing Approved for Sorrento Therapeutics, Inc.

Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors

Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Recent updates

Final DIP Financing Approved for Sorrento Therapeutics, Inc.

Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors

Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso

Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R Mzl)

Sorrento Therapeutics, Inc. Announces Full Enrollment of Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), Second Generation Oral Mpro Inhibitor, as Standalone Treatment for COVID-19

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Therapeutics, Inc.(NasdaqCM:SRNE) dropped from S&P Biotechnology Select Industry Index

Sorrento Therapeutics Received Written Notice from the Staff of The Nasdaq Stock Market LLC

Sorrento Therapeutics, Inc., Annual General Meeting, Apr 06, 2023

Sorrento Therapeutics, Inc. Releases Unblinded Phase 1B Study Data of Its Oral Main Viral Protease Inhibitor, OVYDSO™ (STI-1558) in Covid Patients

Sorrento Therapeutics Receives FDA Clearance to Initiate Clinical Trials with A Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus

Sorrento Therapeutics, Inc. Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented At Asian Congress of the European Society for Medical Oncology (Esmo)

Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from A Phase IB Study in China with STI-1558

No longer forecast to breakeven

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$5.00

No longer forecast to breakeven

Less than half of directors are independent

Sorrento Therapeutics, Inc., Annual General Meeting, Dec 15, 2022

Sorrento Therapeutics, Inc. Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with Sti-1558, an Oral Mpro Inhibitor as A Standalone Oral Treatment and Prevention of Covid-19 Without the Need for A Ritonavir Booster

Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M

Sorrento Therapeutics, Inc. Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients

Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures At 50% of the Standard Dose for Patients (7 of 7) with an Inadequate Response to Subcutaneous Injections

Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial

Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103

Sorrento Therapeutics, Inc. Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib for the Treatment of Advanced Non-Small Cell Lung Cancer

Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC

Sorrento Therapeutics, Inc. Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients

Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading

Sorrento Therapeutics, Inc. announced delayed 10-Q filing

Sorrento Therapeutics, Inc. Announces the Completion of the SAD Portion of the Phase 1 Study of Its Oral Main Viral Protease (Mpro) Inhibitor, the STI-1558

Is Sorrento Therapeutics (NASDAQ:SRNE) A Risky Investment?

Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19

Sorrento Therapeutics: The Enigma

Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical

Sorrento Therapeutics, Inc. Announces First Subject Dosed in A Phase I Clinical Study of Sti-1558, an Oral Mpro Inhibitor as A Standalone Treatment and Prevention of Covid-19 Without Co-Administration of Ritonavir Booster

Less than half of directors are independent

Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors

Sorrento Therapeutics, Inc. Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)

Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern

Sorrento Therapeutics, Inc. Announces That It Has Received Clearance from the FDA for Its Investigational New Drug Application for Intravenous (Iv) Sti-9167

Sorrento Therapeutics Announces the Appointment of Laura Hamill to Its Board of Directors

Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients with Severe Pneumonia Due to Covid-19

Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues

Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure

Sorrento Therapeutics, Inc. announced delayed annual 10-K filing

Sorrento Therapeutics, Inc Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) acquired an unknown majority stake in Zhengzhou Fortune Bioscience Co., Ltd..

Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) completed the acquisition of Virex Health, Inc.

Sorrento Announces its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron

Sorrento Therapeutics, Inc. Announces Covishield (STI-9167), A Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron and Omicron (+R346K) Variants of Sars-Cov-2

Sorrento Therapeutics, Inc. Announces Completion of Enrollment in US Phase 2 Clinical Trial for Covi-Drops and Achievement of Interim Analysis Threshold in the UK

Brazilian Health Regulatory Agency Authorizes Sorrento Therapeutics, Inc.'s Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)

Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors